<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644475</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV001DIM2008</org_study_id>
    <nct_id>NCT00644475</nct_id>
  </id_info>
  <brief_title>Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension</brief_title>
  <official_title>Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND The effects of ACE-inhibitors on fibrinolysis are well documented. Experimental&#xD;
      and clinical studies have shown that ACE inhibitors induce a reduction in plasma PAI-1 levels&#xD;
      in many cardiovascular diseases, like hypertension, coronary heart disease, and heart&#xD;
      failure. Their effects on t-PA are more controversial, due to the fact that t-PA exists in&#xD;
      several forms, including free and bound to PAI-1. Indeed an increase in t-PA activity has&#xD;
      been observed in humans and it seems related to bradykinin increase which is known to&#xD;
      stimulate endothelial t-PA synthesis. These favourable effects on fibrinolysis could be&#xD;
      related not only to the Angiotensin II reduction and the bradykinin increase but also to the&#xD;
      improvement in insulin sensitivity, as insulin has been suggested as one of the main&#xD;
      regulators of fibrinolytic activity.&#xD;
&#xD;
      To date conflicting results have been reported about the effects of ARBs on fibrinolysis.&#xD;
      Some studies have reported small improvements, others no significant effect. These&#xD;
      conflicting results may be due to possible methodological bias but a possible&#xD;
      pathophysiological explanation might be that receptor subtypes other than AT1 mediate the&#xD;
      effect of Angiotensin-II on endothelial PAI-1 expression, i.e. the AT4 receptors, and during&#xD;
      AT1 receptor blockade there is an important increase not only of Angiotensin-II, but also of&#xD;
      all its catabolites including Angiotensin IV. The dissimilar effects on of ACE Is and ARBs&#xD;
      may also depend on their different action on the RAS and their different effect on insulin&#xD;
      sensitivity: ACE-Is improve insulin sensitivity, while the majority of ARBs have been&#xD;
      reported to have a neutral effect. Moreover, unlike ACE-Is, ARBs do not affect the metabolism&#xD;
      of bradykinin, which is known to stimulate t-PA synthesis and release.&#xD;
&#xD;
      AIM OF THE STUDY The aim of this study is to verify the effect of imidapril compared to&#xD;
      candesartan on insulin sensitivity, evaluated through the euglycemic hyperinsulinemic clamp,&#xD;
      and on fibrinolysis, evaluated through the plasma PAI-1 and t-PA activity, in mild to&#xD;
      moderate hypertensive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PAI-1 level and t-PA activity time course changes</measure>
    <time_frame>Desmopressin and Clamp venous blood samples will be taken for all patients between 08.00 and 09.00 at 0 and 12 weeks; week 0, 1, 2, 4, 8, and 12 for the others</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t-PA activity at the desmopressin test</measure>
    <time_frame>Desmopressin and Clamp venous blood samples will be taken for all patients between 08.00 and 09.00 at 0 and 12 weeks; week 0, 1, 2, 4, 8, and 12 for the others</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity state through euglycemic hyperinsulinemic clamp method</measure>
    <time_frame>Desmopressin and Clamp venous blood samples will be taken for all patients between 08.00 and 09.00 at 0 and 12 weeks; week 0, 1, 2, 4, 8, and 12 for the others</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure changes</measure>
    <time_frame>At 0, 1, 2, 4, 8, and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imidapril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidapril</intervention_name>
    <description>tablets; 5, 10, 15, 20 mg; od; 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Not yet registered in Italy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>tablets; 8, 16, 24, and 32 mg; od; 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Registered in Italy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  DBP ≥ 90 &lt; 110 mmHg and SBP ≥ 140 &lt; 180 mmHg&#xD;
&#xD;
          -  Normal Body Mass Index (BMI) (≤ 25 Kg/m2)&#xD;
&#xD;
          -  Normal kidney function (Creatinine Clearance &gt; 80 ml/min)&#xD;
&#xD;
          -  Normocholesterolemia (TC &lt; 250 mg/dl)&#xD;
&#xD;
          -  At least one of the following risk factor:&#xD;
&#xD;
               -  age (M &gt; 55 years)&#xD;
&#xD;
               -  smoking&#xD;
&#xD;
               -  family history of premature CV disease&#xD;
&#xD;
               -  echocardiographic LVH&#xD;
&#xD;
               -  carotid wall thickening (IMT &gt; 0.9 mm)&#xD;
&#xD;
               -  ankle/brachial BP &lt; 0.9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Overweight or obese state (BMI ≥ 25 Kg/m2)&#xD;
&#xD;
          -  Suspected history of allergy to the ARBs, or ACEs&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Renal, hepatic, endocrine, or gastrointestinal disease&#xD;
&#xD;
          -  Women who are pregnant and lactating&#xD;
&#xD;
          -  Women child-bearing potential&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  AMI and/or stroke in the previous 6 months&#xD;
&#xD;
          -  CHD&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD</last_name>
    <phone>+39 0382 502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberto Fogari, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD</last_name>
      <phone>+39 0382 502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Fogari, MD</last_name>
      <phone>+39 0382 526217</phone>
      <email>r.fogari@unipv.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Derosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>March 25, 2008</last_update_submitted>
  <last_update_submitted_qc>March 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Giuseppe Derosa/Aggregate Professor of Internal Medicine</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Imidapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

